Maze Therapeutics Q2 2026: Net Loss Widens to $44.7M, Cash Runway Extended with $494.9M in Reserves
MAZE has more than doubled off its 52-week low of $12.81.
Summary
Maze Therapeutics reported a wider Q2 net loss of $44.7M on higher R&D spending, while holding $494.9M in cash. The company initiated a Phase 2 trial for MZE782 and disclosed the upcoming termination of its Neurocrine partnership.
Key Events · Earnings and Guidance · MAZE
-
Q2 Net Loss Widens
Net loss reached $44.7M in Q2 2026, compared with $33.7M in Q2 2025, driven by increased R&D ($34.9M vs $28.1M) and G&A ($13.1M vs $8.4M) expenses.
-
Strong Cash Position
Cash, cash equivalents and marketable securities totaled $494.9M as of June 30, 2026, following a $144.6M equity raise and $40M term loan draw in H1 2026.
-
License Revenue from Shionogi Milestone
Recognized $20M in license revenue in H1 2026 upon dosing of the first patient in Shionogi's Phase 2 study of MZE001 in Pompe disease.
-
MZE782 Phase 2 Initiated
A Phase 2 proof-of-concept trial of MZE782 in PKU patients was initiated in August 2026; topline data are expected in 2027.
Analysis · MAZE · Life Sciences
Maze Therapeutics' Q2 2026 10-Q shows a net loss of $44.7 million, up from $33.7 million a year ago, as higher R&D and G&A expenses accompany the advancement of its clinical pipeline. The balance sheet remains robust with $494.9 million in cash and equivalents, strengthened by a $144.6 million equity raise in April and a $40 million term loan. License revenue of $20 million was recognized from a Shionogi milestone. Key pipeline developments include the initiation of a Phase 2 trial for MZE782 in PKU and the planned termination of the Neurocrine license agreement. Management believes existing cash is sufficient for at least 12 months, though the widening loss trajectory highlights the capital-intensive nature of its development programs.
At the time of this filing, MAZE was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.81 to $53.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.